1
|
Ni L, Jing S, Zhu L, Yang X, Wang X, Tu S. The Immune Change of the Lung and Bowel in an Ulcerative Colitis Rat Model and the Protective Effect of Sodium Houttuyfonate Combined With Matrine. Front Immunol 2022; 13:888918. [PMID: 35844499 PMCID: PMC9280623 DOI: 10.3389/fimmu.2022.888918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 05/30/2022] [Indexed: 01/19/2023] Open
Abstract
Objective To explore the immune change of lung injury of Ulcerative colitis (UC) by observing the changes of inherent immunity and adaptive immunity of the lung and bowel in UC rat models after the treatment of Sodium Houttuyfonate combined with Matrine. Method UC rat models were established with the mucous membrane of colon allergize combined with TNBS-alcohol enteroclysis for 1 week and 5 weeks. 1-week experimental rats were divided into normal group and model group, 5/each group. 5-weeks experimental rats were divided into normal group, model group, Sodium Houttuyfonate (2.9mg/ml) combined with Matrine (1.47mg/ml), and positive control sulfasalazine (10mg/ml), 5/each group. All rats were administered by gavage for 5 weeks. The histopathological and fibrotic changes in the lung and bowel were observed, and the expressions of Tumor Necrosis Factor (TNF)- α, interleukin (IL)-8 in the lung, bowel, and serum were detected by radio-immunity and immunohistochemistry, and the mRNA expressions of Toll-like receptor (TLR)-4, nuclear factor kappa (NF-κB), Macrophage migration inhibitory factor (MIF), Mucosal addressing cell adhesion molecule-1 (MadCAM1) and Pulmonary surfactant protein-A (SP-A) in the lung and bowel were detected by Real time-PCR. Result Compared with the normal group, the model rats had significant histopathological and fibrotic changes both in the lung and bowel, and all treatment groups were improved. After treatment, TLR4, IL-8, MIF, and TNF-α in the lung decreased (P<0.05); NF-KB, IL-8, and MIF in the bowel increased (P<0.05); MadCAM1 both in lung and bowel decreased (P<0.05); SP-A decreased in bowel and increased in the lung (P<0.05). Conclusion The cause of lung injury in this model was found to be related to inherent immunity and adaptive immunity, while the cause of bowel injury in this model was found to be mainly related to adaptive immunity. Sodium Houttuyfonate combined with Matrine could improve bowel and lung injury.
Collapse
Affiliation(s)
- Lulu Ni
- Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, China
| | - Shan Jing
- Department of Internal Medicine of Traditional Chinese Medicine (TCM), Nantong Hospital, Nantong, China
| | - Li Zhu
- Department of Internal Medicine of Traditional Chinese Medicine (TCM), Dong- zhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Xue Yang
- Department of Internal Medicine of Traditional Chinese Medicine (TCM), Third Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China
| | - Xinyue Wang
- Department of Internal Medicine of Traditional Chinese Medicine (TCM), Dong- zhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Su Tu
- Department of Emergency, the Affiliated Wuxi NO 2 People’s Hospital of Nanjing Medical University, Wuxi, China
- *Correspondence: Su Tu,
| |
Collapse
|
2
|
von Wichert P. Bronchial Diseases are Insufficiently Defined with the Term COPD. Int J Chron Obstruct Pulmon Dis 2021; 16:1349-1352. [PMID: 34025120 PMCID: PMC8132574 DOI: 10.2147/copd.s298210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Accepted: 04/28/2021] [Indexed: 11/29/2022] Open
Abstract
This paper discusses the basic thoughts behind the so-called diagnosis of COPD in relation to cause and course of the disease and questions the value of this functional defined terminology. Instead, the terminology should be based on morphology in the broadest sense including all methods suitable to describe pathological processes to understand the cause of bronchial diseases. The diagnosis COPD is only helpful in relation to therapeutic measures.
Collapse
|
3
|
Russo I, Carrizzo A, Bochicchio S, Piazza O, Lamberti G, Barba AA, Vecchione C, Zeppa P, Iovino P, Bucci C, Santonicola A, Ciacci C. siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease. Transl Med UniSa 2018; 17:25-33. [PMID: 30083520 PMCID: PMC6067069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Evidence in inflammatory bowel diseases (IBD) supports a connection between inflammation and cancer due to the alteration of the cell cycle with loss of control at the G1/S checkpoint. In this study, we analyze the expression and modulation of CyD1 and E2F1 in colon explants from Crohn's disease (CD) patients. We used ex vivo culture of colon explants from 4 CD patients and 2 healthy controls, stimulated with lipopolysaccharide from Escherichia Coli (EC-LPS). Commercial siRNAs for CyD1 and E2F1 inhibition were encapsulated in Invivofectamine® and in purposely produced nanoliposomal vectors to silencing CyD1 and E2F1 expression. Western blot analysis was used to investigate the effect of siRNA on CyD1, E2F1 and cyclooxygenase 2 (COX-2) expression. In CD patients colon explants, CyD1 and E2F1 increased after the inflammatory stimulus but siRNA silencing attenuated their expression and controlled the COX-2 expression too. These data represent a prelimiary exploration of in vitro siRNA use.
Collapse
Affiliation(s)
- Ilaria Russo
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Albino Carrizzo
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Sabrina Bochicchio
- Department of Industrial Engineering, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) – ITALY,Department of Pharmacy, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY
| | - Ornella Piazza
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Gaetano Lamberti
- Department of Pharmacy, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY
| | - Anna Angela Barba
- Department of Industrial Engineering, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) – ITALY
| | - Carmine Vecchione
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Pio Zeppa
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Paola Iovino
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Cristina Bucci
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Antonella Santonicola
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Carolina Ciacci
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| |
Collapse
|
4
|
Russo I, Carrizzo A, Bochicchio S, Piazza O, Lamberti G, Barba AA, Vecchione C, Zeppa P, Iovino P, Bucci C, Santonicola A, Ciacci C. siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease. Transl Med UniSa 2018; 17:22-30. [PMID: 30050877 PMCID: PMC6056255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Evidence in inflammatory bowel diseases (IBD) supports a connection between inflammation and cancer due to the alteration of the cell cycle with loss of control at the G1/S checkpoint. In this study, we analyze the expression and modulation of CyD1 and E2F1 in colon explants from Crohn's disease (CD) patients. We used ex vivo culture of colon explants from 4 CD patients and 2 healthy controls, stimulated with lipopolysaccharide from Escherichia Coli (EC-LPS). Commercial siRNAs for CyD1 and E2F1 inhibition were encapsulated in Invivofectamine® and in purposely produced nanoliposomal vectors to silencing CyD1 and E2F1 expression. Western blot analysis was used to investigate the effect of siRNA on CyD1, E2F1 and cyclooxygenase 2 (COX-2) expression. In CD patients colon explants, CyD1 and E2F1 increased after the inflammatory stimulus but siRNA silencing attenuated their expression and controlled the COX-2 expression too. These data represent a prelimiary exploration of in vitro siRNA use.
Collapse
Affiliation(s)
- Ilaria Russo
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Albino Carrizzo
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Sabrina Bochicchio
- Department of Industrial Engineering, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) – ITALY,Department of Pharmacy, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY
| | - Ornella Piazza
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Gaetano Lamberti
- Department of Pharmacy, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) - ITALY
| | - Anna Angela Barba
- Department of Industrial Engineering, University of Salerno, via Giovanni Paolo II, 132, Fisciano (SA) – ITALY
| | - Carmine Vecchione
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Pio Zeppa
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Paola Iovino
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Cristina Bucci
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Antonella Santonicola
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| | - Carolina Ciacci
- Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, 84081, Baronissi (SA), Italy, IRCCS Neuromed, Pozzilli (IS), 86077, Italy
| |
Collapse
|
5
|
McAleer JP, Kolls JK. Contributions of the intestinal microbiome in lung immunity. Eur J Immunol 2017; 48:39-49. [PMID: 28776643 DOI: 10.1002/eji.201646721] [Citation(s) in RCA: 141] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 06/12/2017] [Accepted: 08/01/2017] [Indexed: 12/20/2022]
Abstract
The intestine is a critical site of immune cell development that not only controls intestinal immunity but extra-intestinal immunity as well. Recent findings have highlighted important roles for gut microbiota in shaping lung inflammation. Here, we discuss interactions between the microbiota and immune system including T cells, protective effects of microbiota on lung infections, the role of diet in shaping the composition of gut microbiota and susceptibility to asthma, epidemiologic evidence implicating antibiotic use and microbiota in asthma and clinical trials investigating probiotics as potential treatments for atopy and asthma. The systemic effects of gut microbiota are partially attributed to their generating metabolites including short chain fatty acids, which can suppress lung inflammation through the activation of G protein-coupled receptors. Thus, studying the interactions between microbiota and immune cells can lead to the identification of therapeutic targets for chronic lower respiratory diseases.
Collapse
Affiliation(s)
- Jeremy P McAleer
- Department of Pharmaceutical Science and Research, Marshall University School of Pharmacy, Huntington, WV, USA
| | - Jay K Kolls
- Tulane School of Medicine, Center for Translational Research in Infection and Inflammation, New Orleans, LA, USA
| |
Collapse
|